BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 12469164)

  • 1. Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin.
    Catino A; Crucitta E; Latorre A; Sambiasi D; Calabrese P; Lorusso V
    Oncol Rep; 2003; 10(1):163-7. PubMed ID: 12469164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
    Vorobiof DA; Rapoport BL; Chasen MR; Slabber C; McMichael G; Eek R; Mohammed C
    Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
    Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
    Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
    Biganzoli L; Cufer T; Bruning P; Coleman RE; Duchateau L; Rapoport B; Nooij M; Delhaye F; Miles D; Sulkes A; Hamilton A; Piccart M
    Cancer; 2003 Jan; 97(1):40-5. PubMed ID: 12491503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of vinorelbine + doxorubicin in advanced breast cancer.
    Lorvidhaya V; Kamnerdsupaphon P; Chitapanarux I; Srisukho S; Trakultivakorn H; Sumitsawan S; Sukthomya V; Tonusin A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1131-8. PubMed ID: 12938268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
    Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
    Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
    Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
    Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
    Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI; Tsolos C; Touloupidis S
    Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
    Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.